Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.42 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | METAP2 | P50579 | 2/20 | 0.42 |
| ▸ | METAP1 | P53582 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL31057897 | 1.00 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1KDM4ECYP2C19HIF1A | |
| SCHEMBL2768593 | 0.98 | — | — | |
| SCHEMBL31648802 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL698331 | 0.96 | ALDH1A1 (0.63) | L3MBTL1ALDH1A1KDM4ECYP2C19HIF1A | |
| SCHEMBL27763191 | 0.81 | ALDH1A1 (0.61) | L3MBTL1ALDH1A1KDM4ECYP2C19HIF1A | |
| SCHEMBL1179397 | 0.77 | — | — | |
| SCHEMBL30463155 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL1178615 | 0.76 | ALDH1A1 (0.95) | L3MBTL1ALDH1A1KDM4ECYP2C19HIF1A | |
| SCHEMBL4212829 | 0.76 | — | — | |
| SCHEMBL765054 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133654-A1 | NEW CRYPTATE-TYPE (BICYCLIC) CHELATORS AND THEIR USE AS LIGANDS FOR MN(II)-BASED MRI CONTRAST AGENTS, 52MN-BASED PET DIAGNOSTIC AGENTS, AND 64/67CU(II)-ISOTOPE-BASED PET DIAGNOSTIC AND THERAPEUTIC AGENTS | DEBRECENI EGYETEM (HU) | 2025-06-26 | — | — | WO | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-9000181-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2015-04-07 | — | — | US | disclosed |
| EP-2013204-B1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2543667-B1 | A method of preparing 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2627653-B1 | 3-AMINO-PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7968587-B2 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators | ELI LILLY AND COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2010-03-18 | — | — | US | disclosed |
| EP-2094658-A2 | TETRAHYDROCYCLOPENTA[B]INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2013204-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008063867-A2 | TETRAHYDROCYCLOPENTA[B] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-4416977-A | ANTIFOGGING AGENT | MITSUBISHI PAPER MILLS, LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069404-A1 | TETRAHYDROCYCLOPENTA[b] INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, NR5A1, MUSK | ADRA1A 14/4885CHRM2 241/4885CHRM3 366/4885 |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ADRA1A 392/4885CHRM2 96/4885CHRM3 198/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | ADRA1A 1602/4885CHRM2 1679/4885CHRM3 2556/4885 |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | ADRA1A 308/4885CHRM2 61/4885CHRM3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.